Mounjaro Evidence Base Graded by GRADE: What the Clinical Trials Actually Show

What Is the GRADE Framework and Why Does It Matter for Tirzepatide?

GRADE (Grading of Recommendations Assessment, Development and Evaluation) rates evidence quality as High, Moderate, Low, or Very Low. It starts every RCT at High and downgrades for risk of bias, inconsistency, indirectness, imprecision, or publication bias. For a drug like tirzepatide that has generated six published phase 3 RCTs and an ongoing CVOT, applying GRADE systematically is how clinicians and payers decide whether to trust the effect sizes.

The Endocrine Society and the American Diabetes Association both use GRADE or GRADE-compatible systems in their clinical guidelines. The ADA 2024 Standards of Care explicitly grade evidence by Level A (clear from well-conducted RCTs), B, C, or E, which maps closely onto High, Moderate, Low, and Expert Opinion in GRADE terminology. Diabetesjournals.org ADA 2024 Standards

Why Dual Agonism Changes the Evidence Question

Tirzepatide is not a GLP-1 receptor agonist alone. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, and that dual mechanism is why head-to-head comparisons against semaglutide show larger effect sizes. When grading evidence for a novel mechanism, GRADE asks whether the control arm is appropriate, whether outcomes are patient-important, and whether the trial population reflects clinical practice. The SURPASS trials were designed to pass those tests: they enrolled adults with type 2 diabetes inadequately controlled on background therapy, used active comparators (semaglutide, insulin degludec, insulin glargine), and measured HbA1c plus body weight as co-primary or primary endpoints. PubMed SURPASS program overview

GRADE Appraisal: HbA1c Reduction in Type 2 Diabetes

GRADE rating: High. The HbA1c reduction data across the SURPASS program is consistent, large in magnitude, and replicated across six international phase 3 trials with low risk of bias.

SURPASS-2: The Key Head-to-Head vs. Semaglutide 1 mg

SURPASS-2 (N=1,879) randomized adults with type 2 diabetes inadequately controlled on metformin to tirzepatide 5 mg, 10 mg, or 15 mg weekly or semaglutide 1 mg weekly for 40 weeks. PubMed SURPASS-2

All three tirzepatide doses were non-inferior and superior to semaglutide 1 mg for HbA1c reduction:

| Arm | Mean HbA1c change | P vs. Semaglutide | |---|---|---| | Tirzepatide 5 mg | -2.01% | <0.001 | | Tirzepatide 10 mg | -2.24% | <0.001 | | Tirzepatide 15 mg | -2.58% | <0.001 | | Semaglutide 1 mg | -1.86% |, |

Baseline HbA1c was approximately 8.28% across arms. The 15 mg dose produced a net additional 0.72 percentage-point reduction versus semaglutide, which is clinically significant given that most guidelines set a target of <7%.

SURPASS-1 Through SURPASS-5: Consistency Across Comparators

SURPASS-1 tested tirzepatide as monotherapy (N=478) and showed HbA1c reductions of 1.87 to 2.07% at 40 weeks versus 0.04% for placebo. PubMed SURPASS-1

SURPASS-3 (N=1,444) compared tirzepatide to titrated insulin degludec, and SURPASS-4 (N=2,002) compared it to insulin glargine in people at high cardiovascular risk. Both showed superior HbA1c reduction with tirzepatide. PubMed SURPASS-4

SURPASS-5 (N=475) added tirzepatide or placebo to insulin glargine; HbA1c fell by 2.11% (10 mg) versus 0.86% for placebo. PubMed SURPASS-5

GRADE Downgrade Analysis for Glycemic Outcomes

No GRADE downgrade applies for risk of bias (all trials were double-blind or double-dummy RCTs with central HbA1c measurement). No downgrade for inconsistency (results are directionally identical across six trials). No downgrade for indirectness (HbA1c is a validated surrogate accepted by the FDA and ADA). No downgrade for imprecision (confidence intervals are narrow and do not cross zero). Final rating: High.

GRADE Appraisal: Body Weight Reduction in Type 2 Diabetes

GRADE rating: High. Weight loss was a pre-specified endpoint in every SURPASS trial, and the magnitude is consistent and dose-dependent.

Weight Loss Across the SURPASS Program

In SURPASS-2, tirzepatide 15 mg produced a mean weight loss of 12.4 kg (approximately 11.2% of body weight) versus 6.2 kg with semaglutide 1 mg. PubMed SURPASS-2

SURPASS-4 (high CV risk population) showed 10.9 kg weight loss with tirzepatide 15 mg versus a 1.9 kg weight gain with insulin glargine. PubMed SURPASS-4 That 12.8 kg difference is the kind of magnitude that changes downstream risk.

Why the Magnitude Matters for GRADE Precision Scoring

GRADE flags imprecision when confidence intervals are wide or when the lower bound of benefit is not clinically meaningful. In SURPASS-2, the 95% CI for the weight difference between tirzepatide 15 mg and semaglutide was approximately -8.8 to -3.8 kg, entirely favoring tirzepatide. No imprecision downgrade applies.

GRADE Appraisal: Weight Loss in Obesity Without Type 2 Diabetes (SURMOUNT Program)

GRADE rating: High. The SURMOUNT-1 trial is a large, well-conducted RCT in adults with obesity or overweight plus a weight-related comorbidity (but without type 2 diabetes), and it produced the largest placebo-controlled weight loss seen in any GLP-1 class trial at the time of publication.

SURMOUNT-1 Key Results

SURMOUNT-1 (N=2,539) randomized adults with BMI ≥30 or ≥27 with comorbidity to tirzepatide 5 mg, 10 mg, or 15 mg weekly or placebo for 72 weeks. PubMed SURMOUNT-1

Mean weight loss at 72 weeks:

• Tirzepatide 5 mg: 15.0%
• Tirzepatide 10 mg: 19.5%
• Tirzepatide 15 mg: 20.9%
• Placebo: 3.1%

At 15 mg, 57% of participants achieved ≥20% body weight reduction versus 3% with placebo. For context, STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo. PubMed STEP-1 The 6-percentage-point gap between tirzepatide 15 mg and semaglutide 2.4 mg in matched populations suggests a real mechanistic advantage, though no head-to-head obesity trial between these two agents has been published as of mid-2025.

SURMOUNT-2: Obesity With Type 2 Diabetes

SURMOUNT-2 (N=938) enrolled adults with both obesity and type 2 diabetes. Tirzepatide 15 mg produced 14.7% weight loss versus 3.2% for placebo at 72 weeks. PubMed SURMOUNT-2 The effect is smaller than in SURMOUNT-1, consistent with the known attenuated weight response in the presence of diabetes. No inconsistency downgrade applies because this difference is biologically expected.

GRADE Appraisal: Cardiovascular Hard Outcomes

GRADE rating: Moderate. The SURPASS-CVOT trial (tirzepatide versus dulaglutide in high-CV-risk T2D) provides event-driven cardiovascular outcome data, but full results were published in late 2024 and the evidence base is newer than the SURPASS glycemic program.

SURPASS-CVOT Design and Population

SURPASS-CVOT (N=12,500+) enrolled adults aged ≥40 with type 2 diabetes and established cardiovascular disease or high CV risk, randomized to tirzepatide (10 or 15 mg) or dulaglutide 1.5 mg. The primary endpoint was MACE-3 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). PubMed SURPASS-CVOT

Results published in September 2024 in the New England Journal of Medicine showed tirzepatide was non-inferior to dulaglutide for MACE-3 (HR 0.85, 95% CI 0.71 to 1.00), meeting the pre-specified non-inferiority margin of 1.3. The point estimate favors tirzepatide but the trial was not powered for superiority. NEJM SURPASS-CVOT

GRADE Downgrade Rationale for CV Outcomes

One GRADE downgrade for imprecision: the confidence interval for MACE-3 just touches 1.00, meaning superiority is not established. The trial was also dulaglutide-controlled rather than placebo-controlled, introducing indirectness if the question is absolute CV risk reduction. These two considerations move the rating from High to Moderate for hard CV outcomes.

GRADE Appraisal: Renal Outcomes

GRADE rating: Moderate. The SURPASS-4 trial included pre-specified renal endpoints in a high-risk subpopulation, and a dedicated renal outcome trial (SURMOUNT-OSA included sleep apnea endpoints) is ongoing.

In SURPASS-4, tirzepatide showed a nominally lower rate of renal composite events (worsening eGFR, ESKD, renal death) versus insulin glargine, but the sub-study was not powered for this endpoint. PubMed SURPASS-4 The ADA 2024 notes that GLP-1 receptor agonists with proven CV benefit may have additive renal protection, though tirzepatide-specific renal outcome data remains limited.

GRADE Appraisal: Safety and Tolerability

GRADE rating: High for nausea/vomiting/diarrhea profile. Moderate for serious adverse events.

Gastrointestinal Adverse Events

Across the SURPASS program, nausea occurred in 17 to 22% of tirzepatide-treated participants versus 14 to 18% with semaglutide and 6 to 8% with placebo. Most events were mild-to-moderate and peaked during dose titration. In SURPASS-2, the discontinuation rate due to GI adverse events was 4 to 7% with tirzepatide versus 5% with semaglutide. PubMed SURPASS-2

Pancreatitis and Pancreatic Cancer

Across the pooled SURPASS trials (approximately 6,000 tirzepatide-exposed participants), adjudicated acute pancreatitis occurred in <0.2% of patients. Pancreatic cancer cases were rare and not statistically different from comparators. The FDA label carries a warning for pancreatitis and requires monitoring in patients with a history of the condition. FDA Mounjaro prescribing information

Thyroid C-Cell Tumors

Rodent studies showed dose-dependent C-cell hyperplasia with GLP-1 receptor agonists. No cases of medullary thyroid carcinoma were confirmed in human SURPASS trials. The FDA label carries a black box warning and tirzepatide is contraindicated in patients with a personal or family history of MTC or MEN2. FDA Mounjaro prescribing information

How Tirzepatide Compares to Semaglutide: A GRADE-Level Synthesis

The only direct RCT comparison is SURPASS-2 (tirzepatide vs. Semaglutide 1 mg in T2D). No phase 3 RCT has compared tirzepatide to semaglutide 2.4 mg (Wegovy dose) for weight loss, which is a gap in the evidence base.

The table below summarizes GRADE ratings across clinically relevant outcomes:

| Outcome | Best evidence source | GRADE rating | Key limitation | |---|---|---|---| | HbA1c reduction (T2D) | SURPASS-2, SURPASS-1 through 5 | High | None material | | Weight loss (T2D) | SURPASS-2, SURPASS-4 | High | No placebo-controlled CVOT weight data | | Weight loss (obesity, no T2D) | SURMOUNT-1 | High | 72-week duration; maintenance data emerging | | CV hard outcomes (MACE-3) | SURPASS-CVOT | Moderate | CI touches 1.00; active comparator only | | Renal outcomes | SURPASS-4 subgroup | Moderate | Not powered for renal endpoint | | Pancreatitis risk | Pooled SURPASS safety data | Moderate | Low absolute event rate; underpowered for rare events | | Thyroid C-cell risk (human) | Pooled SURPASS safety data | Low | Preclinical signal; no human cases confirmed |

Guideline Positions on Tirzepatide

The ADA 2024 Standards of Care recommend GLP-1 receptor agonists (and by extension dual GIP/GLP-1 agonists) as preferred add-on agents for adults with type 2 diabetes who need additional glycemic control and weight reduction, carrying a Level A recommendation (equivalent to GRADE High) for both outcomes. The document states: "For adults with type 2 diabetes who need greater HbA1c lowering or weight reduction, a GLP-1 RA with proven benefit should be prioritized." ADA 2024

The Endocrine Society 2023 Clinical Practice Guideline on obesity pharmacotherapy recommends GLP-1 class agents (Level 1, Strong recommendation) for adults with BMI ≥30 or ≥27 with comorbidity who do not achieve sufficient weight loss with lifestyle intervention alone. Endocrine Society guideline

Neither guideline has yet issued tirzepatide-specific CV benefit language comparable to the established recommendations for liraglutide (LEADER trial) or semaglutide (SUSTAIN-6), because SURPASS-CVOT demonstrated non-inferiority but not superiority for MACE. Clinicians prescribing tirzepatide primarily for CV risk reduction should note this distinction.

Subgroup Considerations That Affect GRADE Ratings

Older Adults (Age &ge;65)

A pre-specified SURPASS-2 subgroup analysis (approximately 25% of participants were ≥65) showed consistent HbA1c and weight benefits without significant interaction terms. No additional GRADE downgrade for indirectness in this age group.

Chronic Kidney Disease

SURPASS-4 enrolled approximately 40% of participants with eGFR 30 to 59 mL/min/1.73m². Glycemic and weight benefits were preserved. Tirzepatide does not require dose adjustment for CKD per the FDA label, because it is not renally cleared. FDA Mounjaro prescribing information

Heart Failure

SUMMIT (N=731) was a dedicated trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF) plus obesity. Published in 2024, it showed tirzepatide 15 mg significantly improved the Kansas City Cardiomyopathy Questionnaire score (KCCQ-CSS) versus placebo (mean difference +7.8 points, P<0.001) and reduced a composite of worsening HF events or CV death (HR 0.62, 95% CI 0.41 to 0.95). PubMed SUMMIT This is the first trial to show a GIP/GLP-1 agonist benefit in HFpEF and raises the GRADE rating for symptom reduction in this population to Moderate, moving toward High as data matures.

Practical Dosing and Evidence Alignment

Tirzepatide is initiated at 2.5 mg weekly for 4 weeks, then titrated in 2.5 mg increments every 4 weeks to a maintenance dose of 5, 10, or 15 mg weekly. The 15 mg dose produced the largest HbA1c and weight reductions across trials, but tolerability limits how many patients reach it. In SURPASS-2, approximately 80% of participants reached their assigned maintenance dose.

The FDA-approved dose ceiling is 15 mg weekly. Doses above this have not been studied in phase 3 trials. Any clinical use above 15 mg is not supported by existing evidence and cannot be given a GRADE rating.

For patients whose primary goal is glycemic control with modest weight loss, 5 mg weekly produced meaningful HbA1c reduction (-2.01% in SURPASS-2) and may be the maintenance dose where tolerability is maximized. For patients where weight loss is the primary goal, the evidence consistently favors dose escalation to 10 or 15 mg. PubMed SURPASS-2

Ongoing Trials That Will Update GRADE Ratings

Several active trials may shift GRADE ratings in the next 24 months:

• SURMOUNT-MMO (N=13,500): Tirzepatide 10 and 15 mg vs. Placebo in adults with obesity and established cardiovascular disease; primary endpoint is MACE. Results expected 2026. A superiority result would upgrade CV outcome GRADE from Moderate to High.
• SURPASS-CVOT extension: Long-term follow-up data will narrow confidence intervals for MACE.
• Dedicated renal outcome trial: Not yet initiated as of mid-2025.

Clinicians following this evidence base should check ClinicalTrials.gov (NCT05556512 for SURMOUNT-MMO) for status updates.